Protagonist Therapeutics, Inc.
PTGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $434,433 | $60,000 | $26,581 | $27,357 |
| % Growth | 624.1% | 125.7% | -2.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $434,433 | $60,000 | $26,581 | $27,357 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $138,128 | $120,161 | $126,215 | $126,006 |
| G&A Expenses | $43,462 | $33,491 | $31,739 | $27,196 |
| SG&A Expenses | $43,462 | $33,491 | $31,739 | $27,196 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $181,590 | $153,652 | $157,954 | $153,202 |
| Operating Income | $252,843 | -$93,652 | -$131,373 | -$125,845 |
| % Margin | 58.2% | -156.1% | -494.2% | -460% |
| Other Income/Exp. Net | $26,565 | $14,697 | $3,980 | $294 |
| Pre-Tax Income | $279,408 | -$78,955 | -$127,393 | -$125,551 |
| Tax Expense | $4,220 | $0 | $0 | $0 |
| Net Income | $275,188 | -$78,955 | -$127,393 | -$125,551 |
| % Margin | 63.3% | -131.6% | -479.3% | -458.9% |
| EPS | 4.47 | -1.39 | -2.52 | -2.65 |
| % Growth | 421.6% | 44.8% | 4.9% | – |
| EPS Diluted | 4.23 | -1.39 | -2.52 | -2.65 |
| Weighted Avg Shares Out | 61,567 | 56,764 | 49,042 | 46,323 |
| Weighted Avg Shares Out Dil | 65,078 | 56,764 | 49,042 | 46,323 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26,315 | $14,898 | $4,060 | $443 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $826 | $3,312 | $3,369 | $2,775 |
| EBITDA | $253,669 | -$90,340 | -$128,004 | -$123,070 |
| % Margin | 58.4% | -150.6% | -481.6% | -449.9% |